Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile

Aghahosseini, Marzieh; Aleyaseen, A; Safdarian, Leli; Moddaress-Hashemi, Shahab; Mofid, Behshad; Kashani, Ladan

doi:10.1007/s00404-010-1579-x

Cited by 11 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports revealed that acarbose and metformin both had some beneficial effects on metabolic syndrome. Our finding was consistent with others [29][30][31][32] and revealed that acarbose and metformin could decrease plasma TC and non-HDL-C slightly in the three groups. The proportion of patients with optimal LDL-C levels with metformin treatment was higher than acarbose in better β-cell function group.…”

Section: Discussionsupporting

confidence: 93%

Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes

Liu

et al. 2019

Endocr J

View full text Add to dashboard Cite

MARCH study suggested that acarbose had similar therapeutic effect on glycated hemoglobin reduction compared to metformin in newly diagnosed type 2 diabetes patients as initial therapy in China. We aimed to investigate whether the efficacy of acarbose was still similar to metformin under different β-cell function status. According to the homeostasis model assessment (HOMA)-β level, 670 patients were divided into better β-cell function group, medium β-cell function group and poor β-cell function group. Patients received acarbose 300 mg/d or metformin 1,500 mg/d for 48 weeks. We found both acarbose and metformin could decrease glycated hemoglobin to similar levels after 48 weeks treatment in all groups. In medium β-cell function group, the decrease of fasting blood glucose after metformin treatment was more significant compared to acarbose (p = 0.040); however, the decrease of post-challenge blood glucose after acarbose treatment was more significant compared to metformin (p = 0.020). Moreover, in poor β-cell function group, the decrease of body weight and body mass index after acarbose treatment were significant compared to metformin (p = 0.004 and p = 0.031, respectively). Therefore, acarbose contributed a similar therapeutic effect to plasma glucose control compared to metformin treatment, even under different β-cell function status.DIABETES MELLITUS (DM), a chronic degenerative metabolic disease, is characterized by hyperglycemia and disorders of carbohydrates metabolism, lipids metabolism, and proteins metabolism caused by insulin resistance (IR) and islet β-cell dysfunction [1]. More than 90% of all DM are type 2 diabetes mellitus (T2DM), which is the most common DM [1]. T2DM caused by the complex interaction among gene, environment and other risk factors. T2DM is accelerated by reduced first-phase insulin release, disordered pulsatility of basal insulin secretion, and increased glucagon secretion [2]. Recent * These authors contributed equally to this work. studies have also emphasised the role of early life factors such as maternal undernutrition, maternal obesity, and gestational diabetes linked to increased risk of diabetes in offspring [3]. Complications associated with T2DM are cardiovascular diseases, diabetic neuropathy, nephropathy, and retinopathy [1].Approximately 7.5% Chinese adults in northwest China interviewed had newly diagnosed T2DM [4]. In Tianjin, China, the percentage for T2DM among schoolaged children was small, however, T2DM related risk factors such as overweight and obesity were very common [5,6]. In a cross-sectional survey in Shanghai adults T2DM was found in 10.1% of subjects with higher incidence among patients with hyperlipidemia. This survey also revealed that there were more males (11.4%) than females (9.2%) [6], more elderly (≥65 years 22.5%) than younger (<55 years, <10%) individuals, and more urban residents (12.8%) than rural residents (5.2%) among T2DM patients [7].Joshi et al. and Wang et al. have reported that metformin/acarbose combination has complimentary mechanisms on...

show abstract

Section: Discussionsupporting

confidence: 93%

Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes

Liu

et al. 2019

Endocr J

View full text Add to dashboard Cite

show abstract

“…Moreover, obesity and insulin resistance are associated with pathogenesis of polycystic ovarian syndrome (PCOS), a condition characterized by a reduced frequency of ovulation, infertility, and hyperandrogenism in premenopausal women (67,68). Metformin's effect on weight in women with PCOS is not as well defined, depending on the population and study design (69)(70)(71)(72)(73)(74). However, a meta-analysis showed that metformin contributed to a decrease of body mass index (BMI) and waist to hip ratio (WHR) in 11 and 7 RCTs of PCOS women respectively, compared to placebo (75).…”

Section: Metformin Decreases Body Weight In Diabetic and Non-diabeticmentioning

confidence: 99%

GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin

et al. 2020

View full text Add to dashboard Cite

“…Currently, metformin is one of the most produced oral antidiabetic drugs in the world and is considered the first-line treatment option managing type 2 diabetes mellitus . Recently, additional therapeutic actions have been described in other pathologies, such as polycystic ovary syndrome, obesity and hepatic steatosis, and potential uses in breast cancer [4, 6, 7]. …”

Section: Introductionmentioning

confidence: 99%

To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents

Arbeláez-Quintero

Palacios

2017

Stroke Research and Treatment

View full text Add to dashboard Cite

Ischemic strokes are major causes of death and disability. Searching for potential therapeutic strategies to prevent and treat stroke is necessary, given the increase in overall life expectancy. Epidemiological reports indicate that metformin is an oral antidiabetic medication that can reduce the incidence of ischemic events in patients with diabetes mellitus. Its mechanism of action has not been elucidated, but metformin pleiotropic effects involve actions in addition to glycemic control. AMPK activation has been described as one of the pharmacological mechanisms that explain the action of metformin and that lead to neuroprotective effects. Most experiments done in the cerebral ischemia model, via middle cerebral artery occlusion in rodents (MCAO), had positive results favoring metformin's neuroprotective role and involve several cellular pathways like oxidative stress, endothelial nitric oxide synthase activation, activation of angiogenesis and neurogenesis, autophagia, and apoptosis. We will review the pharmacological properties of metformin and its possible mechanisms that lead to neuroprotection in cerebral ischemia.

show abstract

Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile

Abstract: The results of this study show that 2,500 mg daily dose of metformin in obese patients with PCOS is effective in the reduction of BMI, waist hip/ratio, LDL, serum insulin and increases SHBG. In general this dose was relatively safe and well tolerated.

Cited by 11 publications

References 17 publications

Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes

Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes

GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin

To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents

Contact Info

Product

Resources

About